ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO)..
BACKGROUND: Lung squamous cell carcinoma (LUSC) is recognized as the major subtypes of non-small cell lung cancer (NSCLC). Circulating tumor cells (CTCs) are critical players in tumor metastasis. A molecular profiling of CTCs has previously identified notch receptor 1 (Notch1) as an important mediator in NSCLC. Therefore, we investigate Notch1 roles in LUSC and its related mechanisms.
METHODS: The serum levels of Notch1 were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The CTCs isolated from blood samples were characterized via an immunofluorescence method. Cell motion was determined using Transwell chambers. The regulatory relationship between Notch1 and zinc finger E-box-binding homeobox 1 (ZEB1) was verified by chromatin immunoprecipitation (ChIP) and luciferase reporter assays. The protein levels were detected by western blotting.
RESULTS: Higher Notch1 expression in patients with LUSC than that in normal controls was observed. Notch1 knockdown inhibited cell motion and epithelial-mesenchymal transition (EMT). ZEB1 transcriptionally activated Notch1. ZEB1 upregulation exacerbated the malignant phenotypes of CTCs.
CONCLUSION: ZEB1-activated Notch1 promotes malignant phenotypes of CTCs in LUSC and indicates poor prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 25(2023), 3 vom: 22. März, Seite 817-829 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gao, Yong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2023 Date Revised 23.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12094-022-02993-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349317364 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349317364 | ||
| 003 | DE-627 | ||
| 005 | 20231226042329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-022-02993-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349317364 | ||
| 035 | |a (NLM)36418641 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gao, Yong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2023 | ||
| 500 | |a Date Revised 23.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). | ||
| 520 | |a BACKGROUND: Lung squamous cell carcinoma (LUSC) is recognized as the major subtypes of non-small cell lung cancer (NSCLC). Circulating tumor cells (CTCs) are critical players in tumor metastasis. A molecular profiling of CTCs has previously identified notch receptor 1 (Notch1) as an important mediator in NSCLC. Therefore, we investigate Notch1 roles in LUSC and its related mechanisms | ||
| 520 | |a METHODS: The serum levels of Notch1 were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The CTCs isolated from blood samples were characterized via an immunofluorescence method. Cell motion was determined using Transwell chambers. The regulatory relationship between Notch1 and zinc finger E-box-binding homeobox 1 (ZEB1) was verified by chromatin immunoprecipitation (ChIP) and luciferase reporter assays. The protein levels were detected by western blotting | ||
| 520 | |a RESULTS: Higher Notch1 expression in patients with LUSC than that in normal controls was observed. Notch1 knockdown inhibited cell motion and epithelial-mesenchymal transition (EMT). ZEB1 transcriptionally activated Notch1. ZEB1 upregulation exacerbated the malignant phenotypes of CTCs | ||
| 520 | |a CONCLUSION: ZEB1-activated Notch1 promotes malignant phenotypes of CTCs in LUSC and indicates poor prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Circulating tumor cell | |
| 650 | 4 | |a Lung squamous cell carcinoma | |
| 650 | 4 | |a Notch receptor 1 (Notch1) | |
| 650 | 4 | |a Zinc finger E-box-binding homeobox 1 (ZEB1) | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a ZEB1 protein, human |2 NLM | |
| 650 | 7 | |a Zinc Finger E-box-Binding Homeobox 1 |2 NLM | |
| 650 | 7 | |a NOTCH1 protein, human |2 NLM | |
| 650 | 7 | |a Receptor, Notch1 |2 NLM | |
| 700 | 1 | |a Cheng, Xinyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Mingfeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g 25(2023), 3 vom: 22. März, Seite 817-829 |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:3 |g day:22 |g month:03 |g pages:817-829 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-022-02993-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 3 |b 22 |c 03 |h 817-829 | ||